Novel n-acetylglucosamine transferase, nucleic acid encoding the same and use thereof in diagnosing cancer and/or tumor
CA 2485142 A1 · Owner: National Institute Of Advanced Industrial Science And Technology · Inventors: Inaba, Niro; Togayachi, Akira; Narimatsu, Hisashi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An enzyme having an activity of transferring N-acetylglucosamine to the nonreducing end of a Gal.beta.1-4Glc or Gal.beta.1-4GlcNAc-group via a .beta.-1,3 bond; a nucleic acid encoding the same; and a method of diagnosing cancer and/or tumor, in particular, digestive cancer and/or tumor using the expression dose of a gene of the above enzyme as an indication. A gene of a novel enzyme having an activity of transferring N-acetylglucosamine to the nonreducing end of a Gal.beta.1-4Glc or Gal.beta.1-4GlcNAc-group via a .beta.-1,3 bond is cloned from human stomach cells and its base sequence is determined. Then this enzyme is expressed. Since this enzyme is scarcely or never produced in …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 14, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 14, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 14, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.